The Korea Advanced Institute of Science and Technology (KAIST) said it signed a memorandum of understanding (MOU) with the International Vaccine Institute (IVI) on Thursday to collaborate on global vaccine research.The MOU is based on the consensus that KAIST, which boasts excellent research capabil
SK bioscience, a vaccine unit of Korea's SK Group, said on Wednesday that the company has entered into a development licensing agreement with Hilleman Laboratories, a Singapore-based vaccine research organization, for the joint development of a second-generation Zaire Ebola virus vaccine.Hilleman La
Kolon Life Science said Tuesday that it has signed an agreement with the Drugs for Neglected Diseases initiative (DNDi), a non-profit drug R&D organization for neglected diseases headquartered in Geneva, to develop a low-cost, sustainable process for the treatment of onchocerciasis, one of the cause
TiumBio, a Kosdaq-listed R&D company focusing on rare diseases, said on Tuesday its investigational treatment for endometriosis, TU2670, has been officially registered by the World Health Organization (WHO) under the International Nonproprietary Name (INN), "merigolix."Merigolix is a gonadotropin-re
NKMAX's natural killer (NK) cell-based therapy, SNK01, is being tested for the effectiveness in the treatment of stroke.NKMAX said on Friday that its U.S. subsidiary, NKGen Biotech, has received Institutional Review Board (IRB) approval of Hospital Angeles in Mexico to treat a stroke patient with SN
Y-Biologics, an antibody-drug development platform company, held a press briefing in Yeouido, Seoul, Thursday, ahead of its initial public offering (IPO) on the Kosdaq market and announced its plans to continue developing antibody drug development through funds secured by the IPO.In the upcoming lis
Celltrion Group said the exercise amount for the share buy-back related to the appraisal right for the merger of Celltrion and Celltrion Healthcare totaled 7.9 billion won ($5.9 million) combined for both companies.The shares tallied due to the appraisal right were approximately 41,972 shares (about
JLK, a Kosdaq-listed medical AI company, has come under fire after its executives sold their shares. The company has apologized and promised to buy back and burn shares, but restoring trust isn't easy.According to the company’s public disclosure on Monday, JLK Vice Presidents Kang Shin-wook and Lee
Hyundai Bioscience, which develops antiviral drugs including treatments for Covid-19, is turning its attention overseas.Hyundai Bioscience said Friday that its U.S. subsidiary, Hyundai Bioscience USA, has applied to the Pandemic Antiviral Discovery Initiative (PAD) to fund its “research and developm
Celltrion said it confirmed the bioequivalence of CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab), compared to the original drug through a global phase 3 clinical trial.The company presented the results during the American College of Allergy, Asthma and Immunology (ACAAI) 2023, held
Guardant Health, a leading precision oncology company headquartered in California, announced Monday that it has launched its blood-based colorectal cancer screening test, Shield, in collaboration with Samsung Medical Center in Korea.Guardant Health’s Shield test, which can be used for regular colore
The government's recent ban on short selling raised expectations about the stock price rise among biopharmaceutical companies.However, the share prices of Kosdaq-listed bio company Altheogen have plummeted recently, raising questions and forcing it to issue a statement to calm the market’s jitters.O
The Celltrion Group's strategic merger of Celltrion and Celltrion Healthcare has garnered a significant boost following the Korean government's recent prohibition on short selling and the companies' announcement of unprecedented quarterly earnings.The positive developments have pushed stock prices o
Samsung Bioepis and Organon said Wednesday the preliminary review of the Supplemental Biologic License Application (sBLA) for interchangeability certification of Humira's biosimilar Hadlima (adalimumab) has been completed, and the review process has begun in earnest.The two companies submitted their
Korean biopharma companies will attend BIO-EUROPE 2023, the last technology trade event of the year, to finalize technology transfer discussions for the year.BIO-EUROPE is the largest pharma and biotech conference in Europe, where leading global biopharma companies and investors share the latest the
NGeneBio announced Monday that it has added a new feature to its next-generation sequencing (NGS) technology-based cancer gene analysis software, NGeneAnalySys. The new feature provides a reporting system that identifies biomarkers for specific therapeutics and immunotherapies.NGeneBio successfully
The government has decided to ban short selling temporarily. It came as a positive response to demands from retail shareholders, who have pointed to short selling as a major culprit for stock price declines.Now, the attention is on how it will affect the stock prices of biotech companies, market ana
The stock prices of biotech and digital health companies, including Lunit, VUNO, JLK, Qurient, GI Innovation, and Geninus, recorded a simultaneous surge, drawing the attention of industry officials and investors.On Thursday, the stock price of medical artificial intelligence (AI) company Lunit rose
Altheogen's meeting with shareholders is one week away, but CEO Park Soon-jae said he would not attend it, raising questions."We would like to announce that our meeting with shareholders scheduled for Nov. 8 has been changed to be led by the vice president for investor relations due to the schedule
AriBio said Wednesday that it has released the results of additional phase 2 analyses of AR1001, an oral treatment for Alzheimer's disease, at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) in Boston, Mass. The investigational drug is being tested in a global phase 3 clinical trial.The compa